Introduction {#Sec1}
============

The orally administered mammalian target of rapamycin (mTOR) inhibitor, everolimus, has clinical activity against a range of malignancies and is currently indicated for the treatment of advanced solid tumors, including renal cell carcinoma and hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer recurring or progressing after nonsteroidal aromatase inhibitor therapy \[[@CR1]--[@CR3]\]. Everolimus is generally well tolerated, with an adverse event profile consisting of manageable side effects such as rash, diarrhea, fatigue, infections, stomatitis, noninfectious pneumonitis, and metabolic abnormalities, mostly mild-to-moderate in severity \[[@CR1], [@CR2], [@CR4], [@CR5]\].

As everolimus has the potential for prolonged use, it is important that physicians are able to recognize, monitor, and effectively manage its adverse events to ensure patient adherence, optimize health-related quality of life, and minimize toxicity. Stomatitis, or more specifically, oral mucositis, is one of the most common and potentially dose-limiting adverse events associated with mTOR inhibitor use, including everolimus \[[@CR6], [@CR7]\], with an incidence as high as 60% reported in trials \[[@CR1], [@CR2], [@CR8], [@CR9]\]. mTOR inhibitor-related mucositis is distinct from typical chemotherapy-related stomatitis, often presenting as distinct, painful, ovoid, superficial, well-demarcated ulcers with a grayish-white pseudomembrane and accompanied by erythema, edema, a burning sensation, and occasional bleeding \[[@CR8], [@CR9]\]. The stomatitis normally develops on mobile, less keratinized mucosa (inner lip, ventral and lateral surfaces of the tongue, and the soft palate) and not on keratinized mucosa (hard palate, gums, and back of the tongue). Mucositis often develops in the first 2 weeks after starting therapy, and symptoms may resolve or level off at approximately 6 weeks \[[@CR10], [@CR11]\].

Part of the management strategy of mTOR-related oral mucositis includes patient education in oral hygiene, diet modifications, and pain management strategies. Interventions to prevent or treat mTOR inhibitor-induced mucositis may include a range of topical preparations, such as corticosteroids and anti-inflammatories, along with supportive treatments such as local anesthetics and topical antimicrobial agents \[[@CR6], [@CR7], [@CR9], [@CR10]\]. Nonsteroidal anti-inflammatory drugs (NSAIDs) or acetaminophen may be useful for pain relief in persistent mucositis, and systemic or intra-lesional treatment with high-dose corticosteroids may be necessary in severe or refractory cases. The use of weak or strong opioids is seldom necessary \[[@CR6], [@CR7], [@CR9], [@CR10], [@CR12]\].

This retrospective study aimed to evaluate the impact of a dexamethasone-containing topical galenical for the management of oral mucositis related to the use of an mTOR inhibitor in patients with metastatic breast or renal cancer.

Methods {#Sec2}
=======

Patients and Treatment Plan {#Sec3}
---------------------------

Eligible patients were receiving everolimus treatment for metastatic breast cancer or metastatic renal cancer between April 3, 2012 and March 17, 2015 at the Unit of Medical Oncology of the Hospital "Annunziata" of Cosenza, Italy. At this hospital, patients receiving everolimus attend a day service clinic dedicated to oral therapies, which allows constant monitoring of appropriate laboratory and clinical parameters and the early detection of toxicities. All patients receiving everolimus were advised on procedures to maintain good oral hygiene, such as using mouthwashes devoid of alcohol (e.g., sodium bicarbonate), flossing after every meal, the careful use of toothpaste and a soft bristle toothbrush, avoidance of products containing hydrogen peroxide, iodine, and derivatives of the thymus, and the avoidance of spicy, fatty or very salty foods. Patients were also educated on how to prevent possible outbreaks of infection (such as periodontal disease and granulomas).

To be included in the analysis, patients with breast cancer received everolimus if they (1) had metastatic disease; (2) were hormone receptor (estrogen receptor, progesterone receptor) positive; (3) had received two previous lines of chemotherapy; (3) had disease progression during or after previous treatment with a non-steroidal aromatase inhibitor; (4) had no symptomatic visceral metastases; (5) were menopausal; (6) had not received everolimus previously; and (7) had normal liver function. Patients with renal cancer were required to be already on treatment with everolimus for the indication of renal cancer.

All breast cancer patients had undergone one or more cycles of chemotherapy or hormonal therapy (not including exemestane). Patients with renal cell carcinoma were given treatment with everolimus after they had presented with disease progression during or after treatment with vascular endothelial growth factor (VEGF)-targeted therapy. Everolimus was prescribed at the standard dose of 10 mg orally once daily, which could be reduced in response to toxicity. Everolimus treatment was suspended only in the case of serious toxicity (≥grade 2). Patients with metastatic breast cancer who were receiving concomitant exemestane received everolimus 10 mg orally once daily plus exemestane 25 mg orally once daily.

Patients underwent a battery of complete blood chemistry tests with particular attention to complete blood count and cholesterol, triglycerides, and blood glucose levels. Patient evaluations to monitor cancer response/disease progression included clinical assessment, computed tomography, and ultrasound mammography.

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013. Informed consent was obtained from all patients for being included in the study.

Galenical Formulation {#Sec4}
---------------------

A topical galenical for the management of mucositis was prepared independently by the pharmacist at our hospital pharmacy according to the procedure and standards of the Italian edition of the European Pharmacopoeia of the Council of Europe, the Italian Society of Pharmacists, and Good Manufacturing Practice. The galenical formulation consisted of dexamethasone 0.024 g, sweet almond oil 1 g, rose honey 15 g, glycerol 15 g, and hydroxyethylcellulose 1.2 g. The resulting odorless, brown, semi-solid, non-sterilized, microbial-controlled preparation was manufactured for application to the oral mucosa. The preparation was stored in a container made of bakelite and kept refrigerated at 2--8 °C.

Patients were instructed to use the galenical preparation at the first appearance of oral mucositis; three times a day for the first 7 days, then twice daily for the next 7 days, then once a day for the following 2 weeks. Application was by a Garrison disposable (bandages, tongue depressors).

Study Endpoints {#Sec5}
---------------

The primary objectives of the analysis were to evaluate the presence, duration and intensity of oral mucositis, both reported by the patient and evaluated by the clinician, during the first three cycles of therapy with everolimus, by assessing duration and severity of symptoms, and to evaluate the usefulness of the topical galenical for the management of oral mucositis in these patients undergoing treatment with everolimus.

Evaluation and Treatment of Mucositis {#Sec6}
-------------------------------------

Data were collected using four specific questionnaire forms at predetermined time points during the first three cycles of everolimus treatment (see Supplementary Material for the four questionnaires used in the study). The written questionnaires were completed on cycle 1 day 1 (baseline), after the first cycle of everolimus treatment (cycle 1 day 8), and after the second and third (last observation) cycles. The questionnaires recorded patient demographics, characteristics of the patients at baseline (primary tumor, staging, metastatic site, performance status, line of treatment, presence/absence of mucositis, systemic analgesic therapy for background disease or mucositis-related pain), time to appearance and objective and subjective assessments of mucositis severity, time to resolution and/or reduction in grade of mucositis, any everolimus dose interruptions required, and the percentage of patients discontinuing everolimus due to mucositis.

Mucositis pain was assessed using the mTOR inhibitor-associated stomatitis (mIAS) scale, specifically developed to assess mTOR inhibitor-related stomatitis \[[@CR13]\]. The scale comprises subjective (patient-rated) and objective (clinician-rated) classification criteria and includes duration of mTOR inhibitor-related ulceration and severity of associated pain, and persistence of lesions and pain. The subjective grading criteria range from grade 0 (no pain) to grade 3 (pain score of ≥6 on a 10-point scale). The objective grading criteria range from grade 0 (no visible lesion) to grade 3 (lesion/s persisting for ≥7 days). MTOR inhibitor dose-modification should be considered only when both subjective and objective assessments are grade 3, indicating persistent lesions with significant pain despite the use of analgesics or other palliative care \[[@CR13]\].

Statistical Analysis {#Sec7}
--------------------

Statistical aggregate analysis of the collected data was used to describe the time course of mucositis development, severity and resolution, treatment interruptions due to mucositis, and the usefulness of the topical galenical for the management of mucositis pain and symptoms.

Results {#Sec8}
=======

Patient Characteristics {#Sec9}
-----------------------

Data from 19 patients (mean age 66.1 years; 84.2% female) were analysed. The majority of baseline characteristics and previous treatments were balanced between the study population (Table [1](#Tab1){ref-type="table"}). However, the primary tumor site was the breast in only the female patients included in the analysis (all were receiving everolimus plus exemestane) while the primary tumor site was the kidney in the three male patients (everolimus only). Metastatic site was bone (42.1%), viscera (31.6%) or both (26.3%). Everolimus was second- or third-line treatment in 79.0% of patients. The majority of men had an Eastern Cooperative Oncology Group (ECOG) performance status of 2, while most women had an ECOG performance status of 1. At baseline, 25.0% of women were receiving pain therapy, primarily with NSAIDs. No men were receiving analgesics at baseline.Table 1Baseline characteristics and treatments of the population by tumor typeCharacteristicBreast cancer (*N* = 16)Renal cancer (*N* = 3)Total (*N* = 19)Mean ± SD age, years64.2 (11.68)75.7 (2.08)66.1 (11.49)Gender, *n* (%) Female16 (100.0)016 (84.2) Male03 (100.0)3 (15.8)Tumor size, *n* (%)^a^ T29 (56.3)09 (47.4) T33 (18.8)3 (100.0)6 (31.6) T44 (25.0)04 (21.1)Nodal status, *n* (%)^a^ N02 (12.5)2 (66.7)4 (21.1) N110 (62.5)1 (33.3)11 (57.9) N23 (18.8)03 (16.8) N31 (6.3)01 (5.3)Metastasis site, *n* (%) Visceral5 (31.3)1 (33.3)6 (31.6) Bone8 (50.0)08 (42.1) Visceral + bone3 (18.8)2 (66.7)5 (26.3)ECOG performance status, *n* (%) 01 (6.3)--1 (5.3) 111 (68.8)1 (33.3)12 (63.2) 24 (25.0)2 (66.7)6 (31.6)Mucositis at baseline, *n* (%)000Mucositis prevention followed, *n* (%)16 (100.0)3 (100.0)19 (100.0)Cancer therapy Everolimus03 (100.0)3 (15.8) Everolimus + exemestane16 (100.0)016 (84.2)Therapy line I2 (12.5)02 (10.5) II6 (37.5)3 (100.0)9 (47.4) III6 (37.5)06 (31.6) IV1 (6.3)01 (5.3) V000 VI1 (6.3)01 (5.3)Received treatment for pain, *n* (%)4 (25.0)04 (21.1)Pain treatment received, *n* (%) NSAIDs4 (25.0)04 (21.1) Opioids1 (6.3)01 (5.3)*ECOG* Eastern Cooperative Oncology Group, *NSAIDs* nonsteroidal anti-inflammatory drugs, *SD* standard deviation^a^Assessed using TNM staging

Time Course of Mucositis Development and Resolution {#Sec10}
---------------------------------------------------

On day 8, after the first cycle of everolimus, two patients (10.5%) had mucositis, which was moderately painful in one patient and severe in the other (Table [2](#Tab2){ref-type="table"}), and with a mucositis degree of grade 2 in one patient and grade 3 in the other. After the second and third cycles, nine (47.4%) and 10 (52.6%) patients, respectively, had mucositis. Mucositis pain was assessed by patients as mild in two cases after the second cycle, while four and six patients after the second and third cycle had moderate mucositis-associated pain, and three and four patients had severe pain after the second and third cycles, respectively. Clinician-assessed grade 3 mucositis (visible oral and/or pharyngeal ulcerations persisting for at least 7 days) was observed in three patients after the second cycle and in four patients after the third cycle. Mucositis was grade 1 or 2 in the other cases (Table [2](#Tab2){ref-type="table"}).Table 2Patients with mTOR inhibitor-associated mucositis, by treatment cycle*n* (%)First cycleSecond cycleThird cyclePatients with mucositis2 (10.5)9 (47.4)10 (52.6)Pain intensity (mIAS Scale^a^; patient-assessed) Grade 0 (no pain)17 (89.5)10 (52.6)9 (47.4) Grade 1 (mild pain)02 (10.5)0 Grade 2 (moderate pain)1 (5.3)4 (21.1)6 (31.6) Grade 3 (severe pain)1 (5.3)3 (15.8)4 (21.1)Mucositis degree (mIAS Scale^a^; clinician-assessed) Grade 0 (no visible stomatitis)17 (89.5)10 (52.6)9 (47.4) Grade 1 (oral and/or pharyngeal heritema without ulcerations)02 (10.5)0 Grade 2 (visible oral and/or pharyngeal ulcerations for a duration of \<7 days)1 (5.3)4 (21.1)6 (31.6) Grade 3 (visible oral and/or pharyngeal ulcerations ≥1 persisting for ≥7 days)1 (5.3)3 (15.8)4 (21.1)*mIAS* mTOR inhibitor-associated stomatitis^a^The mIAS Scale was specifically developed to measure mTOR inhibitor-associated stomatitis \[[@CR13]\]

Patients received everolimus administered orally by continuous daily dosing. A Kaplan--Meier survival analysis showed that the estimated time to the development of mucositis was a mean of 29.6 (median 18.0) days (Fig. [1](#Fig1){ref-type="fig"}). A Cox regression analysis using gender, age, performance status, tumor size, node status and treatment line as covariates, found that only tumor size significantly influenced time to mucositis onset (Table [3](#Tab3){ref-type="table"}): time to development of mucositis was significantly higher in patients with bigger tumor size (*T* = 4) than in patients with the smallest cancers. It must be noted here that, due to the small sample size, this latter analysis should be considered exploratory.Fig. 1Kaplan-Meier estimates of time to the development of everolimus-related mucositis Table 3Cox regression analysis for time to mucositisVariables in the equation*β*SEWald*df*SigExp(*β*)95% CI for Exp(*β*)LowerUpperGender0.5410.9370.33310.5641.7180.27410.790Age0.0530.0293.30010.0691.0550.9961.117ECOG--0.6900.6281.20810.2720.5020.1471.716Tumor size**1.3960.5636.13710.0134.0371.33812.180**Node status0.4160.4820.74510.3881.5160.5893.900Line0.5940.4102.09610.1481.8110.8114.044Time: time to mucositis onsetStatus: mucositis y/nCovariates: gender, age; performance status; tumor size (T); node status (N); treatment lineOnly tumor size (bold) significantly influenced time to mucositis onset*CI* confidence interval, *df* degrees of freedom, *SE* standard error of the mean, *sig* significance, *Exp* exponential

In one of the patients (50.0%) who had mucositis at day 8 of the first cycle, mucositis resolved during the second cycle of therapy (Fig. [2](#Fig2){ref-type="fig"}). All the patients with mucositis at the second cycle had the event resolve during the third cycle of therapy. The Kaplan--Meier survival analysis showed that the estimated time to resolution of mucositis was a mean of 31.4 (median 30.0) days (Fig. [2](#Fig2){ref-type="fig"}). The only patient who did not have resolution of mucositis during the third cycle of therapy experienced severe pain and grade 3 mucositis at day 8. No variation of mucositis severity was observed at the second cycle of therapy in this patient, but at the third cycle mucositis pain was decreased to moderate severity and the degree of mucositis was grade 2.Fig. 2Kaplan-Meier estimates of time to mucositis resolution

Interruption of Therapy {#Sec11}
-----------------------

Only one patient (5.3%) required suspension of everolimus treatment on day 8 of therapy due to everolimus-induced mucositis. After each of the second and third cycles two patients (10.5%) had to suspend everolimus treatment. No everolimus dose reductions for mucositis were necessary.

Pain Therapy by Cycle {#Sec12}
---------------------

Systemic pain therapy for cancer-related pain was required by four patients (21.1%) during the first and second cycles and by three patients (15.8%) during the third cycle. Pain therapy for everolimus-induced mucositis was required by two patients (10.5%) during the first cycle, six patients (31.6%) in the second cycle and eight patients (42.1%) during the third cycle (Table [4](#Tab4){ref-type="table"}). In all cases, NSAIDs were the only analgesics prescribed for mucositis-related pain.Table 4Systemic pain therapy by cyclePain therapy, *n* (%)First cycleSecond cycleThird cycleFor cancer4 (21.1)4 (21.1)3 (15.8) NSAIDs4 (21.1)4 (21.1)3 (15.8) Opioids1 (5.3)1 (5.3)1 (5.3)For mucositis2 (10.5)6 (31.6)8 (42.1) NSAIDs2 (10.5)6 (31.6)8 (42.1)*NSAIDs* nonsteroidal anti-inflammatory drugs

Discussion {#Sec13}
==========

All patients undergoing everolimus therapy in our study were provided with the combination of standardized suggestions for the prevention of mucositis and the use of the galenical preparation, as part of the support offered by our outpatient clinic dedicated to effectively managing and monitoring the administration of oral therapies. This allowed not only the disease patterns of everolimus-related mucositis to be identified and responded to more readily but, most importantly, in almost all cases there was no need to interrupt everolimus treatment. When mucositis occurred, the use of a novel preparation formulated with a corticosteroid (dexamethasone) and rose honey enabled rapid resolution of the mucositis with minimal need for systemic analgesic use. No patient needed opioids for mucositis pain. In those patients who required analgesics for everolimus-related mucositis, common NSAIDs (nimesulide, ketorolac, aspirin) were all that were required to control pain.

As with other mTOR inhibitors, oral mucositis can be a significant dose-limiting adverse event of everolimus therapy. For example, in three recent trials of everolimus plus exemestane in women with advanced breast cancer, 39.8--56.0% of patients experienced at least one episode of everolimus-related mucositis, which was grade 3/4 in approximately 8% of patients \[[@CR1], [@CR14], [@CR15]\]. This is similar to that reported in patients with renal cell carcinoma \[[@CR2]\]. Dose reductions because of mucositis were necessary in over 20% of patients, and everolimus treatment interruptions for a median of 7--17 days were necessary in approximately 40--60% \[[@CR1], [@CR14], [@CR15]\]. In contrast, no patient in our study had a mucositis-related dose reduction, and after the first, second, and third cycles of therapy, only 5.3%, 10.5% and 10.5% of patients required treatment interruptions.

Of interest, in an interim analysis of the BRAWO study, a large, German non-interventional study, which will ultimately enroll 3000 patients with advanced breast cancer receiving everolimus plus exemestane, recommendations on stomatitis prevention similar to those in our study were given to 86.8% of patients. A total of 39.8% of patients had at least one mucositis event, which was grade 2 in 17.0% and grade 3 in 3.4%. In addition to dose reduction or treatment interruption, a range of therapeutic interventions for mucositis were utilized, alone or in combination, including non-drug mouthwashes, cooling strategies such as sucking ice, and systemic or topical drug interventions (not further specified) \[[@CR14]\].

The use of topical or systemic treatment with corticosteroids has been shown to be successful in resolving mucositis in the majority of patients with mTOR inhibitor-related mucositis \[[@CR6], [@CR7], [@CR9], [@CR10], [@CR12], [@CR16]\], and our findings show that early intervention with a dexamethasone-containing galenical preparation is effective in managing mucositis. By integrating appropriate instruction on good oral hygiene designed to prevent mucositis, effective monitoring for the development of mucositis, and the provision of an effective treatment for use at the first signs of mucositis into the management plan of all patients undergoing treatment with everolimus, treatment adherence can be improved to help ensure the best therapeutic outcome. Furthermore, in some, if not all cases, a galenical preparation such as that used in our institution will be more cost-effective than proprietary formulations.

Although the retrospective study design, small patient numbers and absence of a control group (due to the fact that all patients at our institution who are receiving everolimus are put on the program described to minimize the impact of mucositis) can be considered a limitation of our analysis, our standardized approach to instructing and supporting patients undergoing everolimus therapy is a study strength, and the specially-prepared galenical formulation significantly limited the negative effects of mucositis.

Conclusions {#Sec14}
===========

The dose-limiting effects of everolimus-related mucositis can be minimized by successfully educating patients about the importance of oral hygiene in combination with an effective medicinal product that can be manufactured in the hospital pharmacy or other galenical laboratory and provided to the patient to be used at the first signs of mucositis.
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